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The Uganda Sickle Surveillance Study analyzed dried blood spots that were collected from
almost 100 000 infants and young children from all 10 regions and 112 districts in the
Republic of Uganda, with the primary objective of determining the prevalence of sickle cell
trait and disease. An overall prevalence of 13.3% sickle cell trait and 0.7% sickle cell disease
was recently reported. The isoelectric focusing electrophoresis technique coincidentally
revealed numerous hemoglobin (Hb) variants (defined as an electrophoresis band that was
not Hb A, Hb F, Hb S, or Hb C) with an overall country-wide prevalence of 0.5%, but with
considerable geographic variability, being highest in the northwest regions and districts. To
elucidate these Hb variants, the original isoelectric focusing (IEF) gels were reviewed to
identify and locate the variant samples; corresponding dried blood spots were retrieved for
further testing. Subsequent DNA-based investigation of 5 predominant isoelectric focusing
patterns identified 2 a-globin variants (Hb Stanleyville II, Asn78Lys; Hb G-Pest, Asp74Asn),
1 b-globin variant (Hb O-Arab, Glu121Lys), and 2 fusion globin variants (Hb P-Nilotic, b31-
d50; Hb Kenya, Ag81Leu-b86Ala). Compound heterozygotes containing an Hb variant plus
Hb S were also identified, including both Hb S/O-Arab and HbS/Kenya. Regional differences
in the types and prevalence of these hemoglobin variants likely reflect tribal ancestries and
migration patterns. Algorithms are proposed to characterize these Hb variants, which will
be helpful for emerging neonatal hemoglobinopathy screening programs that are under
way in sub-Saharan Africa.
Introduction
A partnership between the Uganda Ministry of Health, Makerere University, and Cincinnati
Children’s Hospital Medical Center (CCHMC) was established to design and conduct the Uganda
Sickle Surveillance Study (US3), a prospective study that assessed the current burden of sickle cell
disease (SCD) at the national level. Between February 2014 and March 2015, nearly 100 000 dried
blood spot (DBS) samples collected from infants and young children in all 10 regions and 112
districts in the Republic of Uganda for the country’s Early Infant Diagnosis HIV program were
reanalyzed by hemoglobin (Hb) isoelectric focusing (IEF) to detect sickle cell trait and SCD. The
recently published results documented an overall national prevalence of 13.3% sickle trait and 0.7%
SCD, but with considerable regional variability.1 Subsequently, a targeted neonatal screening
program has begun in the highest burden districts in the central and northern regions, along with
increased emphasis on clinical care and training as part of an emerging national sickle cell strategy
for Uganda.
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In addition to establishing the prevalence of sickle cell trait and SCD,
the DBS samples in the US3 study were scored as Hb variants if the
IEF pattern revealed at least 1 band that was clearly distinct from Hb A,
Hb F, Hb S, or Hb C. The overall study prevalence of these Hb variants
was 0.5% with substantial geographic variability across the country,
ranging from 0.1% of samples in the SouthWestern Region to 1.8% in
the West Nile Region.1
Given the migratory history and tribal structure of Uganda’s
population, we hypothesized that individual Hb variants would
differ across the country, but would likely be clustered by region.
Defining their clinical importance, either in the heterozygous state
with normal Hb A or in the compound heterozygous state with Hb
S, would require molecular identification of individual variants. In
the current report, we describe the elucidation and geospatial
mapping of the 5 most commonly observed Hb variants found in
the US3 study. Our results allow the creation of algorithms to assist
the identification of common IEF-based Hb variants, which are




The acquisition, laboratory techniques, and analysis of DBS
samples for the US3 study were previously described in detail.1,2
For each DBS sample, the Hb pattern on IEF electrophoresis was
scored as normal, trait, disease, or variant; the latter designation
required the presence of at least 1 IEF band that did not correlate
to the Hb A, Hb F, Hb S, or Hb C controls that were run on each
gel and consensus by 2 independent reviewers. Samples that
contained sickle Hb and variant Hb were designated as disease,
given the potential for clinical manifestations. Following completion
of the US3 study, a secondary objective was the elucidation of Hb
variants. The US3 database was queried to locate samples scored
as variants. Samples were transported as deidentified specimens
to CCHMC for further laboratory analysis. Subsequent Hb and
genetic analyses were performed with oversight from an in-
stitutional review board–approved protocol at both CCHMC and
Makerere University.
HPLC analysis
Each Hb variant was first investigated using high-performance liquid
chromatography (HPLC) to establish the Hb pattern and allow
comparison with known published variants using a previously
established method.3 After 50 mL of freshly prepared Mobile Phase
A (Bis-Tris with potassium cyanide) was added to 2 3-mm punches
from each DBS, the samples were incubated at room temperature
for 60 minutes and then centrifuged at 13 000g for 3 minutes. The
eluted Hb was pipetted into a Waters 150-mL insert and placed
in a 12 3 32 mm glass vial. Samples were analyzed on a PolyCAT
A cation exchange column (PolyLC, Inc., Columbia, MD) using an
Alliance Separation Module (model 2690/2695, Waters Corpora-
tion, Milford, MA). Absorbance was detected at 405 nm using
a Waters dual wavelength absorbance detector and the data
analyzed using Empower software (Waters Corporation). Assay
controls included a Hb retention time control (AFSC Control,
Helena Laboratories, Beaumont, TX) and Hb quantitation controls
(Lyphocheck Hemoglobin A2 Control levels 1 and 2; Bio-Rad
Laboratories, Hercules, CA).
Description of techniques for DNA-based
confirmation and findings
Genomic DNA was isolated from two 3 mm punches, following a
protocol from Instagene (Bio-Rad Laboratories) that was adapted
for DNA extraction from DBS samples. The primary modifications
include initial suspension in 1 mL of PBS 0.1% Tween (Sigma-
Aldrich, St. Louis, MO), and addition of 65 mL of Instagene Matrix.
The purified DNA was not quantified before use in polymerase
chain reaction (PCR)-based methods because of low concentra-
tion. For each Hb variant sample, the predicted globin exons were
first amplified using flanking primers, followed by direct Sanger
sequencing of the PCR products for confirmation. After each
particular missense mutation or fusion protein was identified, a
more rapid PCR-based technique was developed using TaqMan
probes or restriction fragment length polymorphisms (RFLPs).
PCR primers and conditions for Hb variants are included in
supplemental Table 1.
In each assay, the PCR reaction was performed in 25 mL volume,
containing 2.5 mL of DNA, 22.5 mL of PCR mix including 0.25 mL of
nucleotides (dNTP Pharmacia 10 mM final), 2.5 mL 10X Buffer
(Qiagen, Hilden Germany), 2 mM of each primer, and 1.25 U Hot
Star Taq Polymerase (Qiagen). A negative control (water), PCR-
positive control, and positive control (DNA sample confirmed by
Sanger sequencing) were included in each assay. Amplification of
the b-globin gene was performed using forward (59-GGT TGG GAT
AAG GCT GGA TT-3) and reverse (59-TTT GCA GCC TCA CCT
TCT TT-39) primers. Hb S mutation (Glu6Val) was evaluated by
TaqMan (rs334) wherein 1 mL of PCR product was added to 6 mL
2XGenotyping master mix, 0.6 mL probe mix, and water according to
the manufacturer’s recommendation (Applied Biosystems, Foster
City, CA). Amplification of a-globin genes was performed using
forward primer (59-CCC GCG CCC CAA GCA TAA AC-39) with
unique reverse primers for a-1 (59-CTG GCA CGT TTG CTG AGG
GAA AA-39) and a-2 (59-GGCACATTCCGGGATAGAGA-39).
Hb Stanleyville II. The Hb Stanleyville II variant was
confirmed by PCR (supplemental Table 1) and RFLP with restriction
enzyme AfeI. Products were digested by adding 10 mL of PCR
product to 10 mL of digest mix (including 2 mL 10X NEB Cut Smart
Buffer, 0.4 mL AfeI; New England BioLabs, Ipswich, MA). The
sample was digested for 3 hours at 37°C followed by heat
inactivation 75°C for 20 minutes. The samples were resolved on a
3% agarose gel with wild-type (WT) remaining uncut with a single
band at 681 base pair (bp) present. Samples that have Hb Stanleyville
II will digest into products of 483 bp and 198 bp, and heterozygous
samples will have both uncut 681 bp and cut products of 483 bp and
198 bp.
HbG-Pest. This variant was confirmed by PCR (supplemental
Table 1) and customized TaqMan probe (rs28928875) in a method
similar to detection of Hb S (rs334).
Hb O-Arab. This variant was confirmed by PCR (supplemen-
tal Table 1) and RFLP analysis with the restriction enzyme EcoRI
(0.3 m, New England BioLabs) in a method identical to Hb
Stanleyville II. The samples were resolved on a 1% agarose gel with
Hb O-Arab remaining uncut with a single band at 1780 bp, whereas
WT samples are digested into 2 bands of 1418 bp and 362 bp.
Heterozygous samples will have both uncut 1780 bp and digested
products of 1418 bp and 362 bp.
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Hb Kenya. The Hb Kenya variant was confirmed by allele-
specific gap PCR (supplemental Table 1).4 The PCR product was
resolved on a 1% agarose gel. Both mutant (209 bp) and WT were
identified in affected samples, indicating heterozygosity for this
mutation.
Hb P-Nilotic. This variant was confirmed by Hb P-Nilotic
allele-specific gap PCR (supplemental Table 1). The PCR product
was resolved on a 1% agarose gel. Both mutant (824 bp) and WT
(923 bp) were identified in affected samples, indicating heterozy-
gosity for this mutation.
Results
Variant prevalence
The country-wide prevalence of Hb variants was 0.5%, ranging from
0.1% of samples collected in the South Western Region to 1.8% in
the West Nile Region (Figure 1).1 Variants were detected in 94 of
112 districts, exceeding 1.0% in 22 districts, and were most
prevalent in the Arua (2.7%), Alebtong (2.9%), and Adjumani
(2.9%) districts in the West Nile region of Uganda.
Variant analysis
During the study period, 458 samples were identified as an Hb
variant (Figure 2). After study completion, 261 variants were
available for analysis, with 71 excluded for several reasons including
absent or poor quality IEF image, database errors, or transcription
errors (eg, mismatch of the sample number or not scored as a
variant on the IEF worksheet). A total of 190 DBS samples with
variant Hb bands on IEF were located, retrieved, and then evaluated
using DNA-based techniques. DNA confirmation of the Hb variant
was obtained in 135 samples, but was not possible in another 43
because of sample degradation; as a result, their classification was
based on IEF alone. Five common IEF patterns were observed and
investigated further (Figure 3).
The first variant pattern, observed in 30% of the samples, included a
variant IEF band located above Hb S with reduced intensity
compared with Hb A. When these variant samples also contained
Hb F, an additional band was observed below Hb S (Figure 3A).
HPLC analysis included a new peak between Hb A and Hb A2
as a broad peak (data not shown). DNA sequencing revealed a
heterozygous A.C mutation within exon 2 of the a-2 gene locus,
corresponding to missense Asn78Lys (Hb Stanleyville II), a known
a-chain variant. For more rapid diagnosis, PCR amplification of the
exon followed by digestion with the AfeI restriction enzyme yielded a
distinct pattern for detection of both heterozygotes and homozy-
gotes (data not shown). Hb Stanleyville II was confirmed in 27
samples and presumed based on the IEF pattern in 25 samples.
The second variant pattern, observed in 10% of samples, included a
new IEF band located just above Hb S, with reduced intensity
compared with Hb A (Figure 3B). In samples containing substantial
amounts of Hb F, an additional faint band was observed below Hb S
(not shown). HPLC analysis included a peak with the same
retention time as Hb S and in a ratio to Hb A typically observed
with a-chain variants (supplemental Figure 1A). DNA sequencing
revealed a heterozygous G.A mutation within exon 2 of the a-1
gene locus, corresponding to missense Asp74Asn (Hb G-Pest), a
known a-chain variant. For rapid diagnosis, PCR primers and a
TaqMan probe were designed to detect this specific mutation. Hb
G-Pest was confirmed in 13 samples and presumed based on IEF
pattern in 9 samples; all presumed samples were confirmed to be
negative for sickle cell trait.
The third variant pattern, observed in only 1% of the samples,
included a new IEF band located just above Hb C, but with
equivalent intensity as Hb A (Figure 3C). HPLC analysis demon-
strated a peak with the same retention time as Hb C (supplemental
Figure 1B). DNA sequencing revealed a heterozygous G.A
mutation within exon 3 of the b-globin gene locus, corresponding
to missense Glu121Lys (Hb O-Arab), a known b-chain variant. For
rapid diagnosis, PCR primers and an EcoRI digest was designed.
Two variant samples were confirmed as Hb O-Arab.
The fourth variant pattern, observed in 27% of the IEF samples, was
a distinct band between Hb S and Hb C, and always less intense
than Hb A (Figure 3D). All of the samples with this pattern had
identifiable Hb F. On HPLC, the variant Hb had the same retention
time as Hb A (supplemental Figure 1C). The fusion gene Ag81Leu-
b86Ala (Hb Kenya) was identified via gap PCR4; this Hb is a known
fusion product between the g-globin and b-globin gene locus. Hb
Kenya was confirmed in 36 samples and presumed based on IEF in
9 additional samples.
The fifth variant pattern, observed in 21% of IEF samples, had a
single IEF band below HbF and slightly decreased in intensity
compared with Hb A (Figure 3E). On HPLC, the variant eluted as a
small peak between Hb A and Hb A2 (supplemental Figure 1D).
Complete sequencing of the a- and b-globin genes revealed no
missense mutations. PCR primers were then prepared to amplify
fusion genes, and products were identified and sequenced. A fusion
product corresponding to b31-d50 was identified (Hb P-Nilotic),
which is a recognized hybrid variant between the b-globin and
d-globin locus. A gap PCR method was designed for rapid
diagnosis. A total of 36 samples were DNA-confirmed as Hb
P-Nilotic.
These 5 Hb variants accounted for 83% of the tested DBS
samples. In most cases, their location in the country was nonuniform
but clustered geographically (Figure 4). For example, Hb P-Nilotic
was found primarily in the northern districts of Uganda, whereas Hb
Kenya and Hb O-Arab were primarily observed in the eastern




Figure 1. Prevalence of variants in 10 regions in Uganda. Prevalence ranged
from 1.76% (West Nile) to 0.12% (South Western).
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identified throughout the country. In the West Nile region, which
had the highest prevalence of Hb variants, Hb Stanleyville II and Hb
P-Nilotic were the most predominant, accounting for 86% of
variants in this region.
Additional DBS samples that contained potential Hb variants
were investigated, but specific mutations could not be identified
(Figure 2). There were 16 samples incorrectly labeled as variant,
including 11 that were confirmed as sickle cell trait, 3 as homozy-
gous SS disease, and 5 with a band reflecting posttranslational
modifications of Hb A. Two samples contained Hb S plus a
variant and should have been designated as disease. Eleven
variants remain unidentified, including several suspected g-chain
variants; however, their identity could not be confirmed because
of degraded Hb and DNA. These unidentified variants were dis-
persed geographically.
After characterizing the most common variants, a diagnostic al-
gorithm was created to aid the recognition and confirmation of Hb
variants (Figure 5). This algorithm was designed to incorporate
exportable techniques including gap PCR, RFLP, and TaqMan
that may be available in a developing molecular laboratory, rather
than more advanced techniques used by a clinical hemoglobin-
opathy laboratory.
Discussion
With increasing awareness of the contribution of SCD to infant and
under-5 mortality rates, hemoglobinopathy screening pilot programs
261 variant samples were
available for analysis
Excluded (n=71)
- Poor quality gel, unable to confirm: 19
- Normal gel, likely data entry error: 35
- Abnormal gel, not a variant (e.g., Hb AS): 17
Variants with interpretable IEF pattern
(n=190)
Variants with DNA confirmation
(n=115)
























modification of Hb A: 5
Sickle trait: 11
Sickle cell disease: 3
Sickle/variant: 2
Figure 2. Flow diagram depicting the flow of samples through analysis.
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Figure 3. Composite of isoelectric focusing images of 5
predominant hemoglobin variants. Each sample is paired
with the AFSC standard. (A) Hb Stanleyville II; (B) sickle trait
(middle lane), Hb G-Pest (right lane); (C) Hb O-Arab; (D) Hb
Kenya; (E) Hb P-Nilotic.
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have now been initiated in several African countries, with the primary
goal of identifying affected children for early intervention. Programs in
Burkina Faso, Benin, Liberia, Angola, Democratic Republic of Congo,
and Uganda have used IEF as the primary method of detecting
pathological Hb variants, especially Hb S and Hb C. Variant Hb
variants are inevitably identified during screening, although there have
been no studies published regarding the types and frequency of
these non-sickle Hb variants.2,5-8 In a prospective newborn screening
cohort in Luanda, Angola, variant Hb variants (not including Hb C)
were detected in 0.07% of samples, although specific variants were
not elucidated.2 A screening program in the Democratic Republic of
Congo included 31 204 infants but did not report any variants by
IEF.8 Variants appear similarly rare in West Africa, with variants
detected in 3/2341 screened individuals in Burkina Faso (1 Hb O,
1 Hb E, 1 other variant),5 and 5/2785 screened individuals in Liberia
(all suspected but unproven a-chain variants).7 A retrospective
review of Hb electrophoresis performed on 27 530 individuals in
Togo between 1996 and 2010 identified 20 variants (10 Hb
K-Woolwich, 7 Hb Korle-Bu, 1 Hb J-Lome, 1 Hb Lepore, 1 Hb
G-Philadelphia).9 Other studies have also reported a small number
of Hb variants.10-12
Hb variants are probably relatively common in Africa and several
hundred have been described in published studies. The largest
study of Hb variants in sub-Saharan Africa was an analysis of Hb
variants from 1800 individuals in western Kenya; this nonrandom
study population included hospitalized patients, medical staff, and
hematology clinic outpatients.13 Using cellulose acetate and citrate
agar electrophoresis, numerous Hb variants were identified, including
Hb Stanleyville II, Hb P-Nilotic, Hb Kenya, Hb O-Arab, Hb J-Nyanza
(aAla21Asp), and d-globin variants HbBabinga (Gly136Asp), Hb A29
(Gly16Arg), and Hb Flatbush (Ala22Glu); genotype frequencies were
not reported because it was a nonrandom population.13 It is likely that
Hb variants may be found at higher frequencies in individuals from
particular tribes; for example, investigations of the Hawazma tribe in
Western Sudan identified Hb O-Arab at 1% and Hb Khartoum at 3%
frequency, whereas the same variants were not present in the Nubu
tribe.14 Hb E has been described sporadically in Congo15 and in
individuals of mixed African-Asian heritage in South Africa and other
nations.16 The g-chain variants are expected to be common in
neonates, with Hb F-Sardinia approaching a frequency of 7.5% in the
Republic of Congo.17
Five predominant patterns of Hb variants were identified in the
Ugandan population. Identification and geospatial mapping of
variants confirmed our hypothesis that the distribution of Hb
variants was nonuniform across regions of Uganda. Our findings
confirm that Hb Kenya is primarily found in the eastern part of
Uganda and around Lake Victoria (Figure 4).4,13 Samples collected
in major cities, including the capital city of Kampala, tended to have
numerous variants, reflecting migration from rural regions to the
urban setting. There was not a direct correlation between districts
with the highest prevalence of SCD and trait and prevalence of Hb
variants.1 It is unclear, therefore, why these Hb variants exist at
such a high prevalence, and what, if any, survival advantage or risk
they offer.
Hb Stanleyville II is a structural a-globin chain variant caused by a
single amino acid substitution (Asn78Lys) in the second exon of
a-2. Its geographic distribution encompasses many regions of
Africa including Uganda, the Democratic Republic of Congo,
Sudan, Kenya, and Angola, but is not restricted to these areas,
reflecting worldwide African migration.18,19 It has been described
in non-African individuals as well, suggesting several points of
origin.19,20 In many cases, this Hb variant is found in association
with –a3.7-thalassemia (rightward) deletion.19 Historically, Hb
Stanleyville II has not been shown to impact hematological
indices or clinical phenotype when occurring in isolation.19,21
Hb G-Pest is an a-chain variant that is the result of a single base
substitution (Asp74Asn) in the second exon of a-1. Hb G-Pest was
first identified in conjunction with another a-chain variant—Hb
J-Buda—and helped demonstrate the presence of 2 a-globin genes.22
This is the first report of its occurrence in sub-Saharan Africa,
having previously described in Brazil, Hungary, and India.22,23
Previous case reports have not identified any hematological or
clinical aberrations.23
Hb O-Arab accounted for 1% of variant samples in our study and
has previously been described throughout northern, eastern, and
western Africa; the Middle East; and the Balkans.24 Heterozygotes
are asymptomatic with mild microcytosis and anemia, but disease
manifestations may occur when coinherited with Hb S, Hb C, or
b-thalassemia.25,26 Individuals who are homozygous for Hb O-Arab
may have mild microcytic anemia, although those with symptomatic
recurrent anemia and jaundice have been described.25,27
Hb Kenya accounted for 27% of all variants and predominates in
the eastern regions of Uganda. Hb Kenya was first described in the
Luo people in western Kenya in 1972, with an estimated prevalence
of up to 1% in the Lake Victoria region.13,28 Several cases have
previously been reported in Uganda.4,13,29 The reason for the
relatively high prevalence of this mutation is unclear. Hb Kenya is
Figure 4. District map of Uganda illustrating type and distribution of
hemoglobin variants. Each circle represents an individual variant. The district of
Kampala is depicted in the lower right corner. Blue circles, Hb Kenya; red circles, Hb
P-Nilotic; orange circles, Hb G-Pest; green circles, Hb Stanleyville II; yellow circles, Hb
O-Arab; gray circles, unidentified variants.
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made of 2 a-globin chains and 2 non–a-variant chains and is the
result of a 22.7-kb deletion from the 39 end of the Ag-globin gene to
the 59 end of the b-globin gene, which reflects nonhomologous
crossover. Hb Kenya is considered a form of hereditary persistence
of fetal Hb resulting from elevated Hb F levels.13 In the largest
cohort of Hb Kenya heterozygotes, individuals had varying levels of
Hb F (5%-28%; mean, 10.2%) and Hb Kenya (5.7%-23.4%; mean,
13.4%).30 Heterozygotes are typically asymptomatic; however,
further correlation regarding impact on hematologic indices is
needed because many previously studied individuals had concom-
itant iron deficiency and a-thalassemia. To date, neither a homo-
zygote for Hb Kenya nor an individual with the proposed “anti-Kenya”
b-g fusion has been identified.13,28
Hb P-Nilotic, an anti-Lepore Hb, has been described in individuals in
Kenya, the Sudan, and the former Belgian Congo as well as kinships
in Mexico and Turkey.31-33 Hb P-Nilotic is a bd fusion that results
from a 54-bp nondeletional crossover event between b31 and d50,
creating a fusion gene. Heterozygotes are asymptomatic.31 In a
cohort of 7 individuals heterozygous for Hb P-Nilotic, the mean
variant Hb was 17% to 18% of total Hb.31 No homozygotes have
been reported.
Variants that have isoelectric points similar to Hb S deserve special
attention because they can lead to false diagnosis of SCD or trait.
Given the proximity to the Hb S band on IEF, it is quite possible
that many individuals with Hb Stanleyville II or Hb G-Pest are
misdiagnosed as having sickle cell trait (Figure 2).34 On HPLC, Hb
G-Pest has the same retention time as Hb S (supplemental
Figure 1A), illustrating the need for DNA-based confirmation and
the advantage of using complementary methods. In lieu of DNA-
based confirmation, we advise IEF samples with an Hb variant be
repeated adjacent to a confirmed sickle cell trait sample and standard
controls with HbA, HbF, HbS, and HbC to guide the identification.
Compound heterozygosity with variant Hb and the Hb S mutation
can be expected, with the resulting hematological phenotype to be
determined in most cases.31 Although not included in our analysis,
we identified several individuals with compound heterozygosity
with Hb S/O-Arab and Hb S/Kenya. Individuals with compound
heterozygotes for Hb S/O-Arab have disease manifestations and
complications similar to homozygous Hb SS disease.26 Individuals
with Hb S/Kenya may be asymptomatic because of the antisickling
effect of Hb F.30,31 The combined amounts of Hb Kenya and Hb F in
Hb S/Kenya heterozygotes is 30% or greater and might account for
their asymptomatic phenotype.30 This protective effect may be
reduced in the setting of iron deficiency, in which there is preferential
production of Hb S over Hb F and Hb Kenya, which may lead to
symptoms.35 There is significant variability in Hb F production in
individuals with Hb Kenya,30 and it is likely that the clinical phenotype
reflects that variability, and this rare compound heterozygous state
needs further study. Compound heterozygosity for Hb S and Hb P-
Nilotic has been reported in a Ugandan child, with Hb S levels of
39%, similar to other S heterozygotes.31 Although not identified in our
analysis, Hb Stanleyville II has been reported in association with Hb
SS, showing 3 major bands in addition to Hb A and F: a band in the
position of Hb S (abS 1 aStanleyville IIbA), a second band between
S and C (aStanleyville IIgA), and a faint band at the C position
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Figure 5. Diagnostic algorithm for confirming hemoglobin variants.
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disease may moderate the disease phenotype by reducing Hb
polymerization and increased mechanical stability18,36; however,
extrapolations regarding hematological or clinical significance are
premature.18,34,37
This study had several limitations, including inability to confirm all
variants by DNA analysis because of sample degradation, and lack
of accompanying red cell indices, clinical information, and family
demographic information. In general, the quality of HPLC from DBS
samples compared with whole blood controls was reduced, and
no d-globin variants, commonly identified based on HPLC alone,
were identified.13 Because variants that contained sickle Hb were
designated as “disease” in the database, we cannot extrapolate
prevalence of variants occurring in conjunction with Hb S. Finally,
Hb variants identified in Uganda cannot be generalized across all of
sub-Saharan Africa; however, it is likely that similar variants are
present in neighboring countries.
As newborn screening efforts for SCD increase in sub-Saharan
Africa, recognition and correct identification of common Hb
variants, particularly those that may be mistaken for Hb S, will
reduce repetitive testing and improve testing accuracy. Our
diagnostic algorithm can help identify the most common variants,
recognizing its limitations for infants who have high levels of HbF
and numerous aberrant bands. This algorithm should serve as a
useful reference for Uganda and other emerging screening
programs across sub-Saharan Africa.
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Sante Trop. 2013;23(3):294-299.
10. Munyanganizi R, Cotton F, Vertongen F, Gulbis B. Red blood cell disorders in Rwandese neonates: screening for sickle cell disease and glucose-6-
phosphate dehydrogenase deficiency. J Med Screen. 2006;13(3):129-131.
11. North ML, Piffaut MC, Duwig I, Locoh-Donou AG, Locoh-Donou AM. Detection of haemoglobinopathies at birth in Togo. Nouv Rev Fr Hematol. 1988;
30(4):237-241.
12. Djembo-Taty M, Tchiloemba M, Galacteros F, Rosa J, Lissouba P. Epidemiologic study of hemoglobinopathies in the Congo in 2,257 newborn infants [in
French]. Nouv Rev Fr Hematol. 1986;28(4):249-251.
13. Kendall AG, de Leeuw NK, Ouna N, Hira P. Hemoglobin variants in western Kenya. Hum Biol. 1980;52(1):53-61.
14. Bayoumi RA, Saha N. Some blood genetic markers of the Nuba and Hawazma tribes of western Sudan. Am J Phys Anthropol. 1987;73(3):
379-388.




 http://ashpublications.org/bloodadvances/article-pdf/1/1/93/877442/advances000950.pdf by guest on 08 O
ctober 2021
15. Gatti F, Vandepitte J, Lehmann H, Gaffney PJ. Hemoglobin E in a Congolese family [in French]. Ann Soc Belges Med Trop Parasitol Mycol. 1968;48(5):
527-534.
16. Bird AR, Ellis P, Wood K, Mathew C, Karabus C. Inherited haemoglobin variants in a South African population. J Med Genet. 1987;24(4):215-219.
17. Lallemant M, Galacteros F, Lallemant-Lecoeur S, et al. Hemoglobin abnormalities. An evaluation on new-born infants and their mothers in a maternity unit
close to Brazzaville (P.R. Congo). Hum Genet. 1986;74(1):54-58.
18. Burchall G, Maxwell E. Haemoglobin Stanleyville II modifies sickle disease phenotype. Pathology. 2010;42(3):310-312.
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